Korean Circ J.  2018 May;48(5):382-394. 10.4070/kcj.2018.0117.

Trends and Outcomes of Transcatheter Aortic Valve Implantation (TAVI) in Korea: the Results of the First Cohort of Korean TAVI Registry

• Yu CW
• Kim WJ
• Ahn JM
• Kook H
• Kang SH
• Han JK
• Ko YG
• Choi SH
• Koo BK
• Chang K
• Kim HS

• KMID: 2414907
• DOI: http://doi.org/10.4070/kcj.2018.0117

Abstract

BACKGROUND AND OBJECTIVES
There has been no nation-wide data on the outcomes of transcatheter aortic valve implantation (TAVI) after commercialization of TAVI in Korea. We report clinical features and outcomes of the first cohort of TAVI performed from Jun 2015 to Jun 2017 in Korea.
METHODS
The first cohort of Korean-TAVI (K-TAVI) registry includes 576 consecutive patients with severe symptomatic aortic stenosis who underwent TAVI from 17 Korean hospitals for 2 years.
RESULTS
Most of TAVI procedures were performed for septuagenarians and octogenarians (90.8%) through transfemoral approach (98.3%). The rate of device success was 92.5% and permanent pacemaker was implanted in 5.6%. In successive years, incidences of paravalvular leakage (PVL) and major bleeding declined. Society of Thoracic Surgeons (STS) score was 5.2 (3.0 to 9.0) and 34.7% of patients had high surgical risk (STS ≥8). One-year all-cause death occurred in 8.9% and was significantly lower in low to intermediate risk one than in high risk (5.4% vs. 15.5%, p < 0.001). The independent predictors of 1-year mortality were age (hazard ratio [HR], 1.087; 95% confidence interval [CI], 1.036-1.141; p=0.001), moderate or severe PVL (HR, 4.631; 95% CI, 1.624-13.203; p=0.004) and end-stage renal disease (HR, 5.785; 95% CI, 2.717-12.316; p < 0.001).
CONCLUSIONS
K-TAVI registry showed favorable 1-year outcomes with decreasing complication rate over time in real-world Korean patients. Two-thirds of patients were low to intermediate surgical risk and showed a significantly lower mortality than the high-risk patients, suggesting the promising future on the expanded indications of TAVI.

Keyword

Aortic valve stenosis; Transcatheter aortic valve replacement; Mortality; Koreans

MeSH Terms

Aged, 80 and over
Aortic Valve Stenosis
Asian Continental Ancestry Group
Cohort Studies*
Hemorrhage
Humans
Incidence
Kidney Failure, Chronic
Korea*
Mortality
Surgeons
Transcatheter Aortic Valve Replacement*

Figure

• 

  Figure 1 Reported TAVI cases over time in Korea. STS = Society of Thoracic Surgeons; TAVI = transcatheter aortic valve implantation.

• 

  Figure 2 Clinical outcomes in whole population of the first cohort of K-TAVI registry. K-TAVI = Koran-transcatheter aortic valve implantation.

• 

  Figure 3 (A) Changes in the degree of PVL till 1-year in the patients who underwent echocardiographic examinations all 3-time points, at discharge, 1-month, and 1-year (n=192). (B) Changes in mean PG and effective orifice area over time (orange line = mean PG; blue line = effective orifice area). PG = pressure gradient; PVL = paravalvular leakage.

• 

  Figure 4 Kaplan-Meier curves of (A) all-cause death, (B) cardiac death, (C) disabling stroke, and (D) all-cause death or disabling stroke according to patient's STS risk score. STS = Society of Thoracic Surgeons.

Reference

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010; 363:1597–1607.

2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011; 364:2187–2198.

3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016; 374:1609–1620.

4. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017; 376:1321–1331.

5. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol. 2007; 50:69–76.

6. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012; 33:2403–2418.

7. Sawa Y, Saito S, Kobayashi J, et al. First clinical trial of a self-expandable transcatheter heart valve in Japan in patients with symptomatic severe aortic stenosis. Circ J. 2014; 78:1083–1090.

8. Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA. 2013; 310:2069–2077.

9. Ludman PF, Moat N, de Belder MA, et al. Transcatheter aortic valve implantation in the United Kingdom: temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012. Circulation. 2015; 131:1181–1190.

10. Takimoto S, Saito N, Minakata K, et al. Favorable clinical outcomes of transcatheter aortic valve implantation in Japanese patients- first report from the Post-Approval K-TAVI Registry. Circ J. 2016; 81:103–109.

11. Sinning JM, Ghanem A, Steinhauser H, et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2010; 3:1141–1149.

12. Van Mieghem NM, van der Boon RM, Nuis RJ, et al. Cause of death after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2014; 83:E277–82.

13. Barbash IM, Finkelstein A, Barsheshet A, et al. Outcomes of patients at estimated low, intermediate, and high risk undergoing transcatheter aortic valve implantation for aortic stenosis. Am J Cardiol. 2015; 116:1916–1922.